<code id='82E605F1E8'></code><style id='82E605F1E8'></style>
    • <acronym id='82E605F1E8'></acronym>
      <center id='82E605F1E8'><center id='82E605F1E8'><tfoot id='82E605F1E8'></tfoot></center><abbr id='82E605F1E8'><dir id='82E605F1E8'><tfoot id='82E605F1E8'></tfoot><noframes id='82E605F1E8'>

    • <optgroup id='82E605F1E8'><strike id='82E605F1E8'><sup id='82E605F1E8'></sup></strike><code id='82E605F1E8'></code></optgroup>
        1. <b id='82E605F1E8'><label id='82E605F1E8'><select id='82E605F1E8'><dt id='82E605F1E8'><span id='82E605F1E8'></span></dt></select></label></b><u id='82E605F1E8'></u>
          <i id='82E605F1E8'><strike id='82E605F1E8'><tt id='82E605F1E8'><pre id='82E605F1E8'></pre></tt></strike></i>

          leisure time

          leisure time

          author:knowledge    Page View:5

          How do cancer drugs work? What makes biotech stocks go up? And why are venture capitalists so optimistic?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week’s big oncology conference in Europe. We also discuss the latest news in the life sciences, including the future of Alzheimer’s disease treatment, a multibillion-dollar deal, and the return of the biotech mega-round.

          advertisement

          For more on what we cover, here’s STAT’s coverage of the European Society for Medical Oncology meeting; here’s more on Roivant Sciences; here’s the latest on biotech venture capital; here’s more on the latest Alzheimer’s data; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          IRA could hurt research into orphan drugs for rare diseases
          IRA could hurt research into orphan drugs for rare diseases

          AdobeThistimelastyear,membersofCongresswereworkingaroundtheclocktodraftandpasstheInflationReductionA

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Popular nasal decongestant doesn't actually relieve congestion

          Sudafedandothercommonnasaldecongestantscontainingpseudoephedrineareondisplaybehindthecounteratapharm